SCHEMBL2409401

SCHEMBL2409401

O=C(Cc1cccc([N+](=O)[O-])c1)c1c(O)c2cccnc2n(-c2ccccc2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.49
NPSR1 Q6W5P4 1/20 0.48
PDE1A P54750 1/20 0.42
PDE1B Q01064 1/20 0.42
TOP2A P11388 1/20 0.42
KMT2A Q03164 3/20 0.41
ALDH1A1 P00352 2/20 0.41
FEN1 P39748 2/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
REN P00797 1/20 0.40
NOX4 Q9NPH5 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2413280 0.91 PDE4A (0.48) PDE4ANPSR1PDE1APDE1BTOP2A
SCHEMBL2408556 0.90 PTGDR2 (0.46) PDE4ANPSR1PDE1APDE1BKMT2A
SCHEMBL2409456 0.86 PDE1A (0.51) PDE4APDE1APDE1BALDH1A1FEN1
SCHEMBL2409299 0.84 TOP2A (0.49) PDE4APDE1APDE1BTOP2AKMT2A
SCHEMBL2412734 0.83 FEN1 (0.43) PDE4APDE1APDE1BKMT2AALDH1A1
SCHEMBL4185752 0.82 TP53 (0.47) PDE4APDE1APDE1BKMT2AFEN1
SCHEMBL2412845 0.82 MAPT (0.45) PDE4ANPSR1PDE1APDE1BKMT2A
SCHEMBL9043978 0.81 TOP2A (0.62) PDE4ATOP2AKMT2AALDH1A1HTT
SCHEMBL2409347 0.81 PDE1A (0.47) PDE4APDE1APDE1BKMT2AALDH1A1
SCHEMBL2416787 0.81 PDE4A (0.61) PDE4ANPSR1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A PDE4A 3/4885NPSR1 1205/4885PDE1A 28/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A PDE4A 3/4885NPSR1 1178/4885PDE1A 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.